Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2015. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the vesting of conditional share awards.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to a specific equity transaction:
- Fair Market Value of ADS: US$47.82 (as of March 5, 2015).
Material Changes
The filing details the vesting and lapping of a Performance Share Plan award made in 2012 to a Director's Connected Person. The three-year performance period concluded on December 31, 2014.
| Director | Connected Person | ADS Awarded | ADS Lapsed |
|---|---|---|---|
| Dr M Slaoui | Mrs K Slaoui | 743 | 1,174 |
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a share plan transaction under Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Verify the total number of ADSs vested versus lapsed for the specific award to Dr M Slaoui and Mrs K Slaoui.
- Confirm the fair market value of US$47.82 per ADS on the vesting date of March 5, 2015.
- Note that this filing does not contain operational or financial performance data for the company.